Trump Faces New Lawsuit Aimed at Blocking Federal Marijuana Rescheduling

A coalition of prohibitionist activists, substance misuse professionals, doctors, and a cannabis-focused biopharmaceutical company has filed a lawsuit against President Donald Trump and federal officials, seeking to halt the administration's plan to reschedule marijuana at the federal level. This legal challenge adds to the mounting opposition that the rescheduling effort has encountered from various quarters, including some state attorneys general and members of Congress. The case highlights persistent divisions over federal cannabis policy, with opponents arguing that rescheduling could undermine public health and safety

The lawsuit comes amid a broader national debate on marijuana legalization. Rep. Mike Flood (R-NE) voiced strong opposition, stating, "it's the worst thing they've ever seen happen," referring to feedback from constituents in states that have legalized cannabis. Meanwhile, some state officials are reconsidering their participation in legal challenges to federal reforms. For example, Louisiana Attorney General Liz Murrill recently withdrew from a lawsuit she had initially filed with Indiana and Nebraska, signaling shifting priorities among state leaders

In contrast, some policymakers view federal rescheduling as a catalyst for broader state-level reforms. Pennsylvania Senator Sharif Street remarked that the Trump administration's move could be "politically good" for legalization efforts in his state, potentially encouraging more Republicans to support cannabis reform. As reported by Marijuana Moment, this sentiment reflects a growing belief that federal action may provide political cover for hesitant lawmakers to back legalization measures locally

Regulatory developments continue to unfold across the country. California Attorney General Rob Bonta issued an opinion clarifying that Indian tribes must obtain state cannabis licenses before engaging in legal commerce, a position released as related legislation advances in the state assembly. Meanwhile, several states—including Illinois, Vermont, and Michigan—are considering or implementing new rules around cannabis sales, testing, and research. On the business front, U.S. Customs and Border Protection ruled in favor of STIIIZY in a patent dispute, while major cannabis companies like Verano Holdings Corp. and Vireo Growth Inc. announced significant stock adjustments

Scientific research and market activity are also shaping the cannabis landscape. Recent studies suggest that CBD may help prevent muscle atrophy and improve outcomes for pediatric epilepsy patients. Massachusetts retailers reported $23 million in adult-use cannabis sales over Patriots’ Day weekend, coinciding with the 4/20 holiday. These figures underscore the sector's economic significance and the ongoing evolution of the industry in response to shifting laws and consumer demand

OG Lab notes that the latest lawsuit against federal rescheduling demonstrates the legal and political complexity of cannabis reform in the U.S. As state and federal actions continue to diverge—and as scientific and business developments add new layers to the debate—stakeholders should closely monitor both court decisions and regulatory changes in the months ahead